$ATYR News

Update: ATyr Pharma Fiscal Q2 Loss Narrows; Announces Restructuring Plans

aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD

aTyr Pharma CFO Jill Broadfoot To Step Down As Of September 30; To Be Succeeded By Brandon Yaras As Of October 1

aTyr Pharma Q2 EPS $(0.11) Beats $(0.12) Estimate

aTyr Pharma And Kyorin Terminate Collaboration Agreement Effective July 30, 2026; Regains Exclusive Global Rights To Efzofitimod

aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026

aTyr Pharma To Present Subgroup Analysis Of Phase 3 EFZO-FIT Study Of Efzofitimod In Pulmonary Sarcoidosis At WASOG 2026 Congress; Submits Phase 3 Protocol To FDA For Efzofitimod In June

aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

aTyr Pharma Q1 EPS $(0.11) Beats $(0.14) Estimate

aTyr Pharma, Inc. (ATYR) Discusses FDA Feedback and Next Steps for Efzofitimod in Pulmonary Sarcoidosis After Phase III Results - Slideshow

aTyr Pharma to Participate in Upcoming Investor Conferences

aTyr Pharma, Inc. (ATYR) Discusses FDA Feedback and Next Steps for Efzofitimod in Pulmonary Sarcoidosis After Phase III Results Transcript

aTyr Pharma Revamps Efzofitimod Path With New Phase III Sarcoidosis Trial

aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting

Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight

aTyr Pharma Spotlights Efzofitimod Phase 3 Learnings, Eyes Mid-April FDA Type C Meeting

Atyr Pharma: Q4 Earnings Snapshot

aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

aTyr Pharma Q4 EPS $(0.14) Beats $(0.16) Estimate

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)